| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking.
|
Neurology
|
2009
|
2.58
|
|
2
|
Chitinase enzyme activity in CSF is a powerful biomarker of Alzheimer disease.
|
Neurology
|
2012
|
2.23
|
|
3
|
CSF glial markers correlate with survival in amyotrophic lateral sclerosis.
|
Neurology
|
2010
|
1.77
|
|
4
|
Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options.
|
Eur J Neurol
|
2009
|
1.76
|
|
5
|
Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.
|
Neurosci Lett
|
1997
|
1.71
|
|
6
|
Axonal damage markers in cerebrospinal fluid are increased in ALS.
|
Neurology
|
2006
|
1.69
|
|
7
|
Transmission of Creutzfeldt-Jakob disease by handling of dura mater.
|
Lancet
|
1993
|
1.52
|
|
8
|
Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity.
|
Ann Neurol
|
1995
|
1.20
|
|
9
|
Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica.
|
J Neurol Neurosurg Psychiatry
|
2008
|
1.08
|
|
10
|
Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis.
|
Neurology
|
1994
|
1.05
|
|
11
|
Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood-CSF barrier dysfunction.
|
J Psychiatr Res
|
2009
|
1.05
|
|
12
|
Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis.
|
Mult Scler
|
2006
|
1.02
|
|
13
|
Lumbar and ventricular CSF protein, leukocytes, and lactate in suspected bacterial CNS infections.
|
Neurology
|
1998
|
1.00
|
|
14
|
EFNS guidelines on disease-specific CSF investigations.
|
Eur J Neurol
|
2009
|
0.99
|
|
15
|
Impact of serum storage conditions on microRNA stability.
|
Leukemia
|
2012
|
0.99
|
|
16
|
Optical coherence tomography does not support optic nerve involvement in amyotrophic lateral sclerosis.
|
Eur J Neurol
|
2013
|
0.96
|
|
17
|
The macrophage activity marker sCD14 is increased in patients with multiple sclerosis and upregulated by interferon beta-1b.
|
J Neuroimmunol
|
2002
|
0.95
|
|
18
|
Early diagnosis of rhinocerebral mucormycosis by cerebrospinal fluid analysis and determination of 16s rRNA gene sequence.
|
Eur J Neurol
|
2007
|
0.95
|
|
19
|
CSF protein biomarkers for proximal axonal damage improve prognostic accuracy in the acute phase of Guillain-Barré syndrome.
|
Muscle Nerve
|
2009
|
0.95
|
|
20
|
Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy.
|
Mult Scler
|
2012
|
0.92
|
|
21
|
Quantitative ultrasonography in focal neuropathies as compared to clinical and EMG findings.
|
Eur J Ultrasound
|
1999
|
0.92
|
|
22
|
Isolated blood-cerebrospinal fluid barrier dysfunction: prevalence and associated diseases.
|
J Neurol
|
2005
|
0.89
|
|
23
|
Gender-specificities in Alzheimer's disease and mild cognitive impairment.
|
J Neurol
|
2008
|
0.88
|
|
24
|
[CXCL13: a biomarker for acute Lyme neuroborreliosis: investigation of the predictive value in the clinical routine].
|
Nervenarzt
|
2014
|
0.88
|
|
25
|
Escalating immunotherapy of multiple sclerosis--new aspects and practical application.
|
J Neurol
|
2004
|
0.88
|
|
26
|
Cerebrospinal fluid proteome profile in multiple sclerosis.
|
Mult Scler
|
2007
|
0.87
|
|
27
|
Matrix metalloproteinase-9 (MMP-9) in human cerebrospinal fluid (CSF): elevated levels are primarily related to CSF cell count.
|
J Neuroimmunol
|
2000
|
0.85
|
|
28
|
Tau protein in cerebrospinal fluid (CSF): a blood-CSF barrier related evaluation in patients with various neurological diseases.
|
Neurosci Lett
|
2001
|
0.85
|
|
29
|
Cisternal S100 protein and neuron-specific enolase are elevated and site-specific markers in intractable temporal lobe epilepsy.
|
Epilepsy Res
|
1999
|
0.84
|
|
30
|
Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis.
|
Mult Scler
|
2005
|
0.83
|
|
31
|
Steroid-responsive hearing impairment in NMO-IgG/aquaporin-4-antibody-positive neuromyelitis optica.
|
J Neurol
|
2012
|
0.82
|
|
32
|
Effects of repeated intrathecal triamcinolone-acetonide application on cerebrospinal fluid biomarkers of axonal damage and glial activity in multiple sclerosis patients.
|
Mol Diagn Ther
|
2014
|
0.82
|
|
33
|
Serial analysis of circulating adhesion molecules and TNF receptor in serum from patients with multiple sclerosis: cICAM-1 is an indicator for relapse.
|
Neurology
|
1994
|
0.81
|
|
34
|
Central inflammation versus peripheral regulation in multiple sclerosis.
|
J Neurol
|
2011
|
0.80
|
|
35
|
Biochemical markers of cerebrovascular injury in sleep apnoea syndrome.
|
Eur Respir J
|
2002
|
0.80
|
|
36
|
Meningeal derived cerebrospinal fluid proteins in different forms of dementia: is a meningopathy involved in normal pressure hydrocephalus?
|
J Neurol Neurosurg Psychiatry
|
2004
|
0.80
|
|
37
|
Expression of the beta-trace protein in human pachymeninx as revealed by in situ hybridization and immunocytochemistry.
|
J Neurosci Res
|
1999
|
0.80
|
|
38
|
Reversible impaired memory induced by pulsed methylprednisolone in patients with MS.
|
Neurology
|
2005
|
0.79
|
|
39
|
Glatiramer acetate (copolymer-1)-specific, human T cell lines: cytokine profile and suppression of T cell lines reactive against myelin basic protein.
|
Neurosci Lett
|
2000
|
0.79
|
|
40
|
A novel presenilin1 mutation (Q223R) associated with early onset Alzheimer's disease, dysarthria and spastic paraparesis and decreased Abeta levels in CSF.
|
Eur J Neurol
|
2009
|
0.79
|
|
41
|
Proteome analysis of cerebrospinal fluid in Guillain-Barré syndrome (GBS).
|
J Neuroimmunol
|
2007
|
0.78
|
|
42
|
The advanced glycation end-product N epsilon-(carboxymethyl)lysine level is elevated in cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
|
Neurosci Lett
|
2004
|
0.78
|
|
43
|
Intercellular adhesion molecule-1 in cerebrospinal fluid--the evaluation of blood-derived and brain-derived fractions in neurological diseases.
|
J Neuroimmunol
|
1998
|
0.77
|
|
44
|
[Current cerebrospinal fluid diagnostics for pathogen-related diseases].
|
Nervenarzt
|
2013
|
0.77
|
|
45
|
Interferon beta-1b modulates serum sVCAM-1 levels in primary progressive multiple sclerosis.
|
Acta Neurol Scand
|
2004
|
0.76
|
|
46
|
An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levels.
|
Exp Neurol
|
2009
|
0.76
|
|
47
|
MxA protein--an interferon beta biomarker in primary progressive multiple sclerosis patients.
|
Eur J Neurol
|
2008
|
0.76
|
|
48
|
Increased glutamine synthetase immunoreactivity in experimental pneumococcal meningitis.
|
Acta Neuropathol
|
1997
|
0.76
|
|
49
|
Applying new research criteria for diagnosis of early Alzheimer's disease: sex and intelligence matter.
|
Int J Alzheimers Dis
|
2009
|
0.75
|
|
50
|
[Female patient with organic psychosyndrome and neurological focal signs after immunosuppressant therapy].
|
Internist (Berl)
|
2008
|
0.75
|
|
51
|
Interferon-beta1b treatment modulates cytokines in patients with primary progressive multiple sclerosis.
|
Acta Neurol Scand
|
2006
|
0.75
|
|
52
|
Establishment of an efficient enzyme-linked immunosorbent assay for the determination of human choline acetyltransferase.
|
J Neuroimmunol
|
1997
|
0.75
|
|
53
|
[Effects of high-dose cortisone therapy on cognition].
|
Nervenarzt
|
2006
|
0.75
|
|
54
|
Glutamine synthetase in experimental meningitis: increased ratio of the subunits 3 and 2 may indicate enhanced activity.
|
Clin Chim Acta
|
2000
|
0.75
|
|
55
|
Natalizumab-associated cerebellar PML: a case report on how to slow down IRIS.
|
J Neurol
|
2015
|
0.75
|
|
56
|
Diagnosis of cerebral toxoplasmosis by detection of Toxoplasma gondii tachyzoites in cerebrospinal fluid.
|
J Neurol
|
2008
|
0.75
|